Yaotang Wang

Array ( [id] => 17336032 [patent_doc_number] => 20220002363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASE [patent_app_type] => utility [patent_app_number] => 17/366844 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272816 [patent_doc_number] => 20210379014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/366650 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426886 [patent_doc_number] => 20220054594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => USE OF AVE0010 FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 [patent_app_type] => utility [patent_app_number] => 17/365282 [patent_app_country] => US [patent_app_date] => 2021-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12145 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18550801 [patent_doc_number] => 20230248801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE [patent_app_type] => utility [patent_app_number] => 18/010399 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436041 [patent_doc_number] => 20230183335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => GLP1R AGONIST NMDAR ANTAGONIST CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/925818 [patent_app_country] => US [patent_app_date] => 2021-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17925818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468821 [patent_doc_number] => 20230203103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => DIAGNOSIS, PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/000358 [patent_app_country] => US [patent_app_date] => 2021-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14645 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593573 [patent_doc_number] => 20220143146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => PEPTIDE YY PHARMACEUTICAL FORMULATIONS, COMPOSITIONS, AND METHODS [patent_app_type] => utility [patent_app_number] => 17/335610 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14249 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17335610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140212 [patent_doc_number] => 20210308223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => PEPTIDE YY PHARMACEUTICAL FORMULATIONS, COMPOSITIONS, AND METHODS [patent_app_type] => utility [patent_app_number] => 17/335753 [patent_app_country] => US [patent_app_date] => 2021-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14303 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17335753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19896844 [patent_doc_number] => 12274739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Pharmaceutical liquid composition of botulinum toxin with improved stability [patent_app_type] => utility [patent_app_number] => 17/326797 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1356 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17326797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18504644 [patent_doc_number] => 11702449 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => Angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient [patent_app_type] => utility [patent_app_number] => 17/322291 [patent_app_country] => US [patent_app_date] => 2021-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6312 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17322291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18886404 [patent_doc_number] => 11865160 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof [patent_app_type] => utility [patent_app_number] => 17/317631 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 76 [patent_no_of_words] => 63881 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434166 [patent_doc_number] => 20230181460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE [patent_app_type] => utility [patent_app_number] => 17/924651 [patent_app_country] => US [patent_app_date] => 2021-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3565 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17924651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420147 [patent_doc_number] => 20230174608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => Polypeptide Derivative Having Dual Receptor Agonistic Action and Use Thereof [patent_app_type] => utility [patent_app_number] => 17/923936 [patent_app_country] => US [patent_app_date] => 2021-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18656220 [patent_doc_number] => 20230302104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => TREATMENT AND/OR PREVENTION OF A DISEASE OR A SYNDROME RELATED TO A VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 17/922269 [patent_app_country] => US [patent_app_date] => 2021-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17922269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383959 [patent_doc_number] => 20220031811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION [patent_app_type] => utility [patent_app_number] => 17/306184 [patent_app_country] => US [patent_app_date] => 2021-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17183868 [patent_doc_number] => 20210330753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => METHODS OF TREATING COVID-19 MEDIATED LUNG DAMAGE USING SURFACTANTS AND NATURAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/242142 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6485 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17242142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18529956 [patent_doc_number] => 20230235023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED ACUTE RESPIRATORY DISTRESS [patent_app_type] => utility [patent_app_number] => 17/918932 [patent_app_country] => US [patent_app_date] => 2021-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17343 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312877 [patent_doc_number] => 20210401925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY [patent_app_type] => utility [patent_app_number] => 17/233134 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19583 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17233134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17154919 [patent_doc_number] => 20210315970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => Hepatitis A Virus Replication Inhibitor Targeting mTOR [patent_app_type] => utility [patent_app_number] => 17/227859 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11691 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17227859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17154923 [patent_doc_number] => 20210315974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH EXENDIN (9-39) [patent_app_type] => utility [patent_app_number] => 17/226164 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17226164 [rel_patent_id] =>[rel_patent_doc_number] =>)